Webcast Alert: Aastrom Announces Fourth Quarter Investor Conference Call.ANN ARBOR, Mich. -- Aastrom Biosciences, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ASTM ASTM abbr. American Society for Testing and Materials ) announces the following Webcast: What: Aastrom Biosciences, Inc. 4th Quarter Fiscal Year 2007 Investor Conference Call When: Monday, September 10, 2007 @ 4:30 pm (EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT ) Where: http://www.vcall.com/IC/CEPage.asp?ID=119955 How: * For live Internet access, simply log on to the web at the address above. * For phone access, interested parties should call toll-free (877) 407-9205 before the start of the call to register and identify themselves as registrants of the "Aastrom Conference Call". Any registered caller on the toll-free line may ask for call operator for directions to be placed in the queue for the Question & Answer session. If calling from outside the U.S., please use the international phone number (201) 689-8054. * To download the podcast, simply log on to the web at the address above. Contact: Investor Relations Department, (734) 930-5777 or mail@aastrom.com If you are unable to participate during the live call, the webcast will be available for replay at http://www.investorcalendar.com/ until December 10, 2007. Through September 21, 2007, the audio replay of the call will be available by dialing toll-free (877) 660-6853, or from outside the U.S. (201) 612-7415. When prompted on the phone, the Account # is: 286, and the Conference ID# is: 252325. Aastrom is a regenerative medicine company developing autologous autologous /au·tol·o·gous/ (aw-tol´ah-gus) related to self; belonging to the same organism. au·tol·o·gous adj. 1. cell products for the repair or regeneration of bone, vascular, cardiac and neural tissues, based on its proprietary Tissue Repair Cell (TRC TRC Noun (in South Africa) Truth and Reconciliation Commission: a commission which encourages people who committed human rights abuses or acts of terror during the apartheid era to reveal the truth about their crimes in return for immunity from prosecution ) Technology. Aastrom's TRC-based products contain a unique cell mixture of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. TRC-based products have been used in over 250 patients to date and are being clinically evaluated for bone regeneration as a result of osteonecrosis osteonecrosis /os·teo·ne·cro·sis/ (os?te-o-ne-kro´sis) necrosis of a bone. os·te·o·ne·cro·sis n. Necrosis of bone. of the femoral femoral /fem·o·ral/ (fem´or-al) pertaining to the femur or to the thigh. fem·o·ral adj. Of or relating to the femur or thigh. head (U.S.: ON-CORE Phase III trial and Spain: pivotal trial), and vascular regeneration related to critical limb ischemia (U.S.: RESTORE-CLI Phase IIb trial and Germany: Phase I/II trial). Aastrom has recently completed a U.S. Phase I/II severe fracture clinical trial, and is also developing programs to address cardiac and neural regeneration indications. TRC-based products have received Orphan Drug Designation from the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for use in the treatment of osteonecrosis of the femoral head and the treatment of dilated cardiomyopathy, a severe chronic disease of the heart. For more information, visit Aastrom's website at www.aastrom.com. (astmc) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion